Construction of dual nanomedicines for the imaging and alleviation of atherosclerosis

References

• Psarros C, Lee R, Margaritis M, et al. Nanomedicine for the prevention, treatment and imaging of atherosclerosis. Maturitas. 2012;73(1):52–60.
   PubMed Web of Science ®Google Scholar
• Fava C, Montagnana M. Atherosclerosis is an inflammatory disease which lacks a common anti-inflammatory therapy: how human genetics can help to this issue. A narrative review. Front Pharmacol. 2018;9:55.
   PubMed Web of Science ®Google Scholar
• Gargiulo S, Gramanzini M, Mancini M. Molecular imaging of vulnerable atherosclerotic plaques in animal models. Int J Mol Sci. 2016;17(9):1511.
   PubMed Web of Science ®Google Scholar
• Taghavie-Moghadam PL, Butcher MJ, Galkina EV. The dynamic lives of macrophage and dendritic cell subsets in atherosclerosis. Ann NY Acad Sci. 2014;1319(1):19–37.
   PubMedGoogle Scholar
• Chung EJ. Targeting and therapeutic peptides in nanomedicine for atherosclerosis. Exp Biol Med (Maywood). 2016;241(9):891–898.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen J, Yang B, et al. In vivo MR and fluorescence dual-modality imaging of atherosclerosis characteristics in mice using profilin-1 targeted magnetic nanoparticles. Theranostics. 2016;6(2):272–286.
   PubMed Web of Science ®Google Scholar
• Wong SW, Sun S, Cho M, et al. H2O2 exposure affects myotube stiffness and actin filament polymerization. Ann Biomed Eng. 2015;43(5):1178–1188.
   PubMed Web of Science ®Google Scholar
• Caglayan E, Romeo GR, Kappert K, et al. Profilin-1 is expressed in human atherosclerotic plaques and induces atherogenic effects on vascular smooth muscle cells. PLoS One. 2010;5(10):e13608.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Joshi N, Chattopadhyay K, et al. A facile synthesis of PEG-coated magnetite (Fe3O4) nanoparticles and their prevention of the reduction of cytochrome c. ACS Appl Mater Interfaces. 2012;4(1):142–149.
   PubMed Web of Science ®Google Scholar
• Gao S. Monodisperse magnetic nanoparticles for biodetection, imaging, and drug delivery: a versatile and evolving technology. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(6):583–609.
   PubMed Web of Science ®Google Scholar
• Park YI, Piao Y, Lee N, et al. Transformation of hydrophobic iron oxide nanoparticles to hydrophilic and biocompatible maghemite nanocrystals for use as highly efficient MRI contrast agent. J Mater Chem. 2011;21(31):11472.
   Web of Science ®Google Scholar
• You DG, Saravanakumar G, Son S, et al. Dextran sulfate-coated superparamagnetic iron oxide nanoparticles as a contrast agent for atherosclerosis imaging. Carbohydr Polym. 2014;101:1225–1233.
   PubMed Web of Science ®Google Scholar
• Lee GY, Kim JH, Choi KY, et al. Hyaluronic acid nanoparticles for active targeting atherosclerosis. Biomaterials. 2015;53:341–348.
   PubMed Web of Science ®Google Scholar
• Lee GY, Kim JH, Oh GT, et al. Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. J Control Release. 2011;155(2):211–217.
   PubMed Web of Science ®Google Scholar
• Jaffer FA, Libby P, Weissleder R. Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(7):1017–1024.
   PubMed Web of Science ®Google Scholar
• Eraso LH, Reilly MP, Sehgal C, et al. Emerging diagnostic and therapeutic molecular imaging applications in vascular disease. Vasc Med. 2011;16(2):145–156.
   PubMed Web of Science ®Google Scholar
• Winter PM, Neubauer AM, Caruthers SD, et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(9):2103–2109.
   PubMed Web of Science ®Google Scholar
• Schiener M, Hossann M, Viola JR, et al. Nanomedicine-based strategies for treatment of atherosclerosis. Trends Mol Med. 2014;20(5):271–281.
   PubMed Web of Science ®Google Scholar
• Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410.
   PubMed Web of Science ®Google Scholar
• He H, Lancina MG, Wang J, et al. Bolstering cholesteryl ester hydrolysis in liver: a hepatocyte-targeting gene delivery strategy for potential alleviation of atherosclerosis. Biomaterials. 2017;130:1–13.
   PubMed Web of Science ®Google Scholar
• Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov. 2011;10(5):365–376.
   PubMed Web of Science ®Google Scholar
• Waksman R, Pakala R, Burnett MS, et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc Radiat Med. 2003;4(1):34–38.
   PubMedGoogle Scholar
• Lobatto ME, Fuster V, Fayad ZA, et al. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov. 2011;10(11):835–852.
   PubMed Web of Science ®Google Scholar
• Seetharaman G, Kallar AR, Vijayan VM, et al. Design, preparation and characterization of pH-responsive prodrug micelles with hydrolyzable anhydride linkages for controlled drug delivery. J Colloid Interface Sci. 2017;492:61–72.
   PubMed Web of Science ®Google Scholar
• Li C, Li H, Wang Q, et al. pH-sensitive polymeric micelles for targeted delivery to inflamed joints. J Control Release. 2017;246:133–141.
   PubMed Web of Science ®Google Scholar
• Dou Y, Chen Y, Zhang X, et al. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis. Biomaterials. 2017;143:93–108.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813–827.
   PubMed Web of Science ®Google Scholar
• Dou Y, Guo J, Chen Y, et al. Sustained delivery by a cyclodextrin material-based nanocarrier potentiates antiatherosclerotic activity of rapamycin via selectively inhibiting mTORC1 in mice. J Control Release. 2016;235:48–62.
   PubMed Web of Science ®Google Scholar
• Prabha G, Raj V. Formation and characterization of beta-cyclodextrin (beta-CD) – polyethyleneglycol (PEG) – polyethyleneimine (PEI) coated Fe3O4 nanoparticles for loading and releasing 5-Fluorouracil drug. Biomed Pharmacother. 2016;80:173–182.
   PubMed Web of Science ®Google Scholar
• Dorokhin D, Hsu S-H, Tomczak N, et al. Visualizing resonance energy transfer in supramolecular surface patterns of β-CD-functionalized quantum dot hosts and organic dye guests by fluorescence lifetime imaging. Small. 2010;6(24):2870–2876.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ma PX. Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective. Adv Drug Deliv Rev. 2013;65(9):1215–1233.
   PubMed Web of Science ®Google Scholar
• Şen Karaman D, Gulin-Sarfraz T, Hedström G, et al. Rational evaluation of the utilization of PEG-PEI copolymers for the facilitation of silica nanoparticulate systems in biomedical applications. J Colloid Interface Sci. 2014;418:300–310.
   PubMed Web of Science ®Google Scholar
• Segers FME, den Adel B, Bot I, et al. Scavenger receptor-AI-targeted iron oxide nanoparticles for in vivo MRI detection of atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2013;33(8):1812–1819.
   PubMed Web of Science ®Google Scholar
• Du H, Liu M, Yang X, et al. The design of pH-sensitive chitosan-based formulations for gastrointestinal delivery. Drug Discov Today. 2015;20(8):1004–1011.
   PubMed Web of Science ®Google Scholar
• Witke W. The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol. 2004;14(8):461–469.
   PubMed Web of Science ®Google Scholar
• Pae M, Romeo GR. The multifaceted role of profilin-1 in adipose tissue inflammation and glucose homeostasis. Adipocyte. 2014;3(1):69–74.
   PubMedGoogle Scholar
• Horrevoets AJ. Profilin-1: an unexpected molecule linking vascular inflammation to the actin cytoskeleton. Circ Res. 2007;101(4):328–330.
   PubMed Web of Science ®Google Scholar
• van Bochove GS, Paulis LE, Segers D, et al. Contrast enhancement by differently sized paramagnetic MRI contrast agents in mice with two phenotypes of atherosclerotic plaque. Contrast Media Mol Imaging. 2011;6(1):35–45.
   PubMed Web of Science ®Google Scholar
• Biasiolli L, Lindsay AC, Chai JT, et al. In-vivo quantitative T2 mapping of carotid arteries in atherosclerotic patients segmentation and T2 measurement of plaque components. J Cardiovasc Magn Reson. 2013; 15(1):69.
   PubMedGoogle Scholar
• Alkhalil M, Biasiolli L, Chai JT, et al. Quantification of carotid plaque lipid content with magnetic resonance T2 mapping in patients undergoing carotid endarterectomy. PLoS One. 2017;12(7):e0181668.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang B, Wang C, et al. Monitoring lipid peroxidation within foam cells by lysosome-targetable and ratiometric probe. Anal Chem. 2015;87(16):8292–8300.
   PubMed Web of Science ®Google Scholar
• Chen WQ, Zhong L, Zhang L, et al. Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol. 2009;156(6):941–951.
   PubMed Web of Science ®Google Scholar
• Jang YJ, Park B, Lee HW, et al. Sinigrin attenuates the progression of atherosclerosis in ApoE(–/–) mice fed a high-cholesterol diet potentially by inhibiting VCAM-1 expression. Chem Biol Interact. 2017;272:28–36.
   PubMed Web of Science ®Google Scholar